Avadel Pharmaceuticals plc

AVDL

IE00BDGMC594

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
7.750 ^USD	-3.12%		-1.90%	-26.26%

Jan. 13	UBS Adjusts Price Target on Avadel Pharmaceuticals to $14 From $22, Maintains Buy Rating	MT
Jan. 10	Top Premarket Decliners	MT

Avadel Pharmaceuticals plc Announces Step Down of Richard Kim as Chief Commercial Officer Effective as of December 31, 2024

December 03, 2024 at 06:03 am EST

On December 2, 2024, Richard Kim notified Avadel Pharmaceuticals plc (the Company) that he will step down as Chief Commercial Officer effective as of December 31, 2024.

Latest news about Avadel Pharmaceuticals plc

UBS Adjusts Price Target on Avadel Pharmaceuticals to $14 From $22, Maintains Buy Rating	Jan. 13	MT
Top Premarket Decliners	Jan. 10	MT
Needham Adjusts Avadel Pharmaceuticals' Price Target to $19 From $22, Keeps Buy Rating	Jan. 09	MT
Avadel Pharmaceuticals Preliminary Q4 Net Product Revenue Rises; 2025 Outlook Set; Shares Fall After Hours	Jan. 08	MT
Avadel Pharmaceuticals plc, Q4 2024 Guidance/Update Call, Jan 08, 2025	Jan. 08
Avadel Pharmaceuticals plc Provides Update on Revitalyz Pivotal Study	Jan. 08	CI
Avadel Pharmaceuticals plc Provides Earnings Guidance for 2025	Jan. 08	CI
Avadel Pharmaceuticals plc Announces Step Down of Richard Kim as Chief Commercial Officer Effective as of December 31, 2024	Dec. 03	CI
UBS Adjusts Price Target on Avadel Pharmaceuticals to $22 From $25, Maintains Buy Rating	Nov. 19	MT
Avadel Pharmaceuticals plc, Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Avadel Pharmaceuticals' Q3 Loss Narrows, Revenue Rises	Nov. 12	MT
Avadel Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation	24-10-31	DJ
Wall Street Set to Open Lower Thursday; Inflation Data Meets Expectations, Initial Jobless Claims Decline	24-10-31	MT
Investors Await Key Inflation, Employment Data as US Futures Move Lower in Thursday's Premarket	24-10-31	MT
Top Premarket Gainers	24-10-31	MT
Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances	24-10-24	CI
Avadel Pharmaceuticals Gets FDA Approval for Lumryz to Treat Cataplexy in Narcolepsy Patients	24-10-17	MT
Avadel Gets Expanded FDA OK of Lumryz for Use in Children	24-10-17	DJ
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy	24-10-17	CI
Avadel Pharmaceuticals plc Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-06-2024 10:00 AM	24-09-06
Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension	24-09-03	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	24-08-28	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	24-08-28	MT
Sector Update: Health Care	24-08-28	MT

Chart Avadel Pharmaceuticals plc

Duration

Period

AVDL: Dynamic Chart

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Employees

154

Sector

Pharmaceuticals

Calendar

2025-03-12 - Q4 2024 Earnings Release (Projected)

More about the company